

CONTACT:

Dept. of Marketing and Communications
+1.484.344.9234

IPS Successfully Delivers a Fast-Paced Project Amid COVID-19

Blue Bell, Pennsylvania, November 19, 2020 – IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, announces the successful delivery of the new process development and testing facility for WuXi Biologics, a leading global open-access biologics technology platform offering end-to-end solutions from concept to commercial manufacturing. WuXi Biologics partnered with IPS to renovate the 33,000 square-foot facility located in King of Prussia, PA, part of the emerging life sciences and biotech hub of the Greater Philadelphia region.



WuXi Biologics' new process development laboratory

The site is the first of three WuXi Biologics facilities in the United States that will open in response to growing customer needs.

IPS executed the project in an extremely tight timeline and overcame the unusual challenges posed by COVID-19 restrictions, including severe limitations and interruptions to construction activities. In spite of those challenges, the IPS EPCMV team managed the site and delivered the project while complying with all safety measures, including IPS COVID-related policies, as well as those imposed by CDC and OSHA.

Even with the disruptions created by the COVID-19 pandemic, IPS' integrated team of EPCMV professionals expedited project activities and completed the renovations and equipment installations in 7 months.

The team met the project deadline, allowing WuXi Biologics to strengthen its ability to support biotech and biopharma partners.

"I couldn't be prouder of our team for their relentless commitment to successfully deliver this important project for our client, WuXi Biologics," stated Dave Goswami, IPS Chairman and CEO. "The project is a great example of our unique brand of integrated EPCMV delivery model and our collaboration with the project delivery supply chain. I want to congratulate Wuxi Biologics on the opening of this new facility that will ultimately benefit patients worldwide."

WuXi Biologics [announced](#) the opening of its new process development and testing lab facility on October 8, 2020.

About IPS

IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill and passion, IPS provides consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in Blue Bell, PA-USA, IPS is one of the fastest-growing companies servicing the life sciences industry with over 1,400 professionals in the US, Canada, Brazil, UK, Ireland, Switzerland, Germany, Singapore, China, and India. Visit our website at www.ipsdb.com.